March 6 Biotech Update- Oh the Humanity

It is Thursday again and as usual I do not have much time to write anything in depth. In general, the broad market looked good but the sector seemed pretty heavy. I cannot shake the feeling that the sector is starting to turn in that the runs higher seem further apart and the intraday dips […]

February 27- A Quick Biotech Update

Thursday’s are always busy and today is no different. I wanted to post a quick update in terms of ECYT. 1. As I noted yesterday, I contacted the company and I did eventually get a response. Essentially, ECYT does not want to discuss anything about the CHMP process with individuals for fear of selective disclosure. […]

February 25 Biotech Update- Some Upcoming Catalysts

It is another day with the sector trading basically in line with market and the real outperformers/underperformers have news associated with them. At this point the real tension in the sector is between the clear continuation of the rally and the fear/expectation of a larger macro correction that will take the sector down with it. […]

February 7 Biotech Update- Recovery Edition

Despite the disappointing jobs report, the market held up fairly well and the biotech sector doing well (and seems to be getting relatively stronger as the day goes on). Large caps appeared to be a little stronger than the broader market, although perhaps that would have been more pronounce if it were not for GILD […]

February 6 Biotech Update- A Mixed Day

It is good day in the market but a bad day for large cap biotechs as most underperformed (large cap pharma was a little different but still not great). Small and mid caps seemed to do better but I would not say that they clearly outperformed the market (but still did better than the large […]

February 3 Biotech Update- The Bloodbath Edition

It was another rough day in the market with a familiar pattern- market weak, large cap biotechs outperforming the broader market and small cap biotechs underperforming. It makes sense in that risk off means selling biotechs but large cap biotechs have a valuation buffer in their growing free cash flow. This is not to say […]